This observational study aims to understand how often certain solid tumors, like colorectal, non-small cell lung, or pancreatic cancer, lose a specific protein called HLA-A*02 (Human Leukocyte Antigen). HLA helps your immune system recognize healthy cells. When cancer cells lose HLA, they can hide from the immune system. Researchers will use Next Generation Sequencing (NGS) on your tumor tissue to check for this HLA loss. If you qualify, you'll also undergo apheresis, a procedure to collect your white blood cells. These collected cells will be stored for potential future use in making CAR T-cell therapy, a type of treatment that uses your own immune cells to fight cancer. This study helps identify patients who might benefit from A2 Biotherapeutics, Inc.'s CAR T-cell therapies.

Study design

This is an observational study involving 200 participants with solid tumors. It is not testing a new treatment, but rather collecting information about your cancer and preparing cells for potential future therapy.

What's involved

You would provide tumor tissue and a blood sample for genetic testing. If eligible, you would also undergo an apheresis procedure to collect your white blood cells.

Compensation

Not stated in the trial record.

Follow-up

Researchers will measure the percentage of participants who can enroll in a CAR T-cell therapy study after apheresis for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.